Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome

Long Wang, Jason Rockwood, Danielle Zak, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Methods: Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at baseline and at the end of the study. PAI-1 activity and sP-selectin and sCD40L levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was no baseline difference in any of the parameters studied. Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 ± 5.2 IU/mL at baseline vs. 21.4 ± 3.9 IU/mL after 8 weeks of treatment). Simvastatin did not alter (P < 0.05) the levels of sP-selectin (111.4 ± 35.9 ng/mL at baseline vs. 118.5 ± 71.2 ng/mL after 8 weeks) or sCD40L (2.0 ± 1.6 ng/mL at baseline vs. 1.5 ± 1.0 ng/mL after 8 weeks). Conclusion: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.

Original languageEnglish (US)
Pages (from-to)149-152
Number of pages4
JournalMetabolic Syndrome and Related Disorders
Volume6
Issue number2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Simvastatin
Plasminogen Activator Inhibitor 1
Volunteers
P-Selectin
CD40 Ligand
LDL Cholesterol
Atherosclerosis
Cardiovascular Diseases
Enzyme-Linked Immunosorbent Assay
Placebos
Ligands
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. / Wang, Long; Rockwood, Jason; Zak, Danielle; Devaraj, Sridevi; Jialal, Ishwarlal.

In: Metabolic Syndrome and Related Disorders, Vol. 6, No. 2, 01.06.2008, p. 149-152.

Research output: Contribution to journalArticle

Wang, Long ; Rockwood, Jason ; Zak, Danielle ; Devaraj, Sridevi ; Jialal, Ishwarlal. / Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. In: Metabolic Syndrome and Related Disorders. 2008 ; Vol. 6, No. 2. pp. 149-152.
@article{5eab406d2bb64a3986a237eeb6d719fd,
title = "Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome",
abstract = "Background: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Methods: Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at baseline and at the end of the study. PAI-1 activity and sP-selectin and sCD40L levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was no baseline difference in any of the parameters studied. Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 ± 5.2 IU/mL at baseline vs. 21.4 ± 3.9 IU/mL after 8 weeks of treatment). Simvastatin did not alter (P < 0.05) the levels of sP-selectin (111.4 ± 35.9 ng/mL at baseline vs. 118.5 ± 71.2 ng/mL after 8 weeks) or sCD40L (2.0 ± 1.6 ng/mL at baseline vs. 1.5 ± 1.0 ng/mL after 8 weeks). Conclusion: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.",
author = "Long Wang and Jason Rockwood and Danielle Zak and Sridevi Devaraj and Ishwarlal Jialal",
year = "2008",
month = "6",
day = "1",
doi = "10.1089/met.2008.0012",
language = "English (US)",
volume = "6",
pages = "149--152",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome

AU - Wang, Long

AU - Rockwood, Jason

AU - Zak, Danielle

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Methods: Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at baseline and at the end of the study. PAI-1 activity and sP-selectin and sCD40L levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was no baseline difference in any of the parameters studied. Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 ± 5.2 IU/mL at baseline vs. 21.4 ± 3.9 IU/mL after 8 weeks of treatment). Simvastatin did not alter (P < 0.05) the levels of sP-selectin (111.4 ± 35.9 ng/mL at baseline vs. 118.5 ± 71.2 ng/mL after 8 weeks) or sCD40L (2.0 ± 1.6 ng/mL at baseline vs. 1.5 ± 1.0 ng/mL after 8 weeks). Conclusion: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.

AB - Background: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Methods: Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at baseline and at the end of the study. PAI-1 activity and sP-selectin and sCD40L levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was no baseline difference in any of the parameters studied. Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 ± 5.2 IU/mL at baseline vs. 21.4 ± 3.9 IU/mL after 8 weeks of treatment). Simvastatin did not alter (P < 0.05) the levels of sP-selectin (111.4 ± 35.9 ng/mL at baseline vs. 118.5 ± 71.2 ng/mL after 8 weeks) or sCD40L (2.0 ± 1.6 ng/mL at baseline vs. 1.5 ± 1.0 ng/mL after 8 weeks). Conclusion: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.

UR - http://www.scopus.com/inward/record.url?scp=44449101643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449101643&partnerID=8YFLogxK

U2 - 10.1089/met.2008.0012

DO - 10.1089/met.2008.0012

M3 - Article

C2 - 18484901

AN - SCOPUS:44449101643

VL - 6

SP - 149

EP - 152

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 2

ER -